Base de dados : MEDLINE
Pesquisa : C10.228 [Categoria DeCS]
Referências encontradas : 15203 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1521 ir para página                         

  1 / 15203 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29465595
[Au] Autor:Dravid AN; Natrajan K; Kulkarni MM; Saraf CK; Mahajan US; Kore SD; Rathod NM; Mahajan US; Wadia RS
[Ad] Endereço:Department of Medicine, Ruby Hall Clinic.
[Ti] Título:Discordant CSF/plasma HIV-1 RNA in individuals on virologically suppressive antiretroviral therapy in Western India.
[So] Source:Medicine (Baltimore);97(8):e9969, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Aim of this study was to estimate the prevalence of cerebrospinal fluid (CSF)/Plasma HIV-1 RNA discordance in virologically suppressed individuals presenting with incident neurologic symptoms.In this retrospective cohort study conducted between March 1, 2009, and March 1, 2017, HIV-1 infected adults exposed to atleast 12 months of antiretroviral therapy (ART) and having plasma viral load (VL) <1000 copies/mL (virologically suppressed) were included. Among these, individuals presenting with neurologic symptoms during follow-up were assessed for CSF/Plasma HIV-1 RNA discordance by measuring HIV-1 RNA in collected plasma and CSF samples. CSF/plasma HIV-1 RNA discordance was defined as either detectable CSF HIV-1 RNA (VL > 20 copies/mL) with an undetectable plasma RNA (complete viral suppression, VL ≤20 copies/mL) or CSF HIV-1 RNA ≥ 0.5 log10 higher than plasma RNA when plasma VL was between 20 and 1000 copies/mL (low-level viremia, LLV).Out of 1584 virologically suppressed patients, 71 (4.4%) presented with incident neurologic symptoms. Twenty out of 71 (28.2%) patients were diagnosed with CSF/Plasma HIV-1 discordance. Median plasma and CSF VL in patients with discordance was 120 [interquartile range (IQR): <20 to 332.5] and 4250 (IQR: 2550.0- 9615.0) copies/mL, respectively. All 9 individuals in which CSF HIV-1 genotypic resistance testing was done showed mutations that would compromise efficacy of prescribed ART regimen. Prevalence of CSF/plasma HIV-1 RNA discordance was higher among neurologically symptomatic patients with plasma LLV as compared with those with complete viral suppression (70% vs 11.8%, P < .001). The risk of discordance was also greater in patients who received protease inhibitor (PI) containing ART (P < .001) and those on ART regimens with central nervous system (CNS) penetration effectiveness (CPE) value <6 (P = .006).CSF/plasma HIV-1 RNA discordance indicates replication of HIV-1 that has adapted to the CNS or has developed antiretroviral drug resistance. Larger studies should be performed to study incidence of discordance in India. This will help in managing patients presenting with neurologic symptoms on suppressive ART with appropriate neuroeffective therapy.
[Mh] Termos MeSH primário: Infecções por HIV/tratamento farmacológico
HIV-1/genética
RNA Viral/sangue
RNA Viral/líquido cefalorraquidiano
Viremia/epidemiologia
[Mh] Termos MeSH secundário: Adulto
Fármacos Anti-HIV/uso terapêutico
Doenças do Sistema Nervoso Central/virologia
Feminino
Infecções por HIV/virologia
Seres Humanos
Índia/epidemiologia
Masculino
Meia-Idade
Prevalência
Estudos Retrospectivos
Carga Viral
Viremia/sangue
Viremia/líquido cefalorraquidiano
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-HIV Agents); 0 (RNA, Viral)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180222
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009969


  2 / 15203 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29275231
[Au] Autor:Pastor M; Fernández-Calle R; Di Geronimo B; Vicente-Rodríguez M; Zapico JM; Gramage E; Coderch C; Pérez-García C; Lasek AW; Puchades-Carrasco L; Pineda-Lucena A; de Pascual-Teresa B; Herradón G; Ramos A
[Ad] Endereço:Departamento de Química y Bioquímica, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, 28925, Alcorcón, Madrid, Spain.
[Ti] Título:Development of inhibitors of receptor protein tyrosine phosphatase ß/ζ (PTPRZ1) as candidates for CNS disorders.
[So] Source:Eur J Med Chem;144:318-329, 2018 Jan 20.
[Is] ISSN:1768-3254
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:A new series of blood-brain barrier permeable molecules designed to mimic the activity of Pleiotrophin in the CNS has been designed and synthesized. These compounds exert their action by interacting with the intracellular domain PD1 of the Protein Tyrosine-Phosphatase Receptor Z1 (PTPRZ1), and inhibiting its tyrosine phosphatase activity. The most potent compounds 10a and 12b (IC = 0,1 µM) significantly increase the phosphorylation of key tyrosine residues of PTPRZ1 substrates involved in neuronal survival and differentiation, and display protective effects against amphetamine-induced toxicity. Docking and molecular dynamics experiments have been used to analyze the binding mode and to explain the observed selectivity against PTP1B. An In vivo experiment has demonstrated that 10a can cross the BBB, thus promoting the possibility of moving forward these candidates for the development of drugs for the treatment of CNS disorders, such as drug addiction and neurodegenerative diseases.
[Mh] Termos MeSH primário: Anti-Inflamatórios não Esteroides/farmacologia
Proteínas de Transporte/farmacologia
Doenças do Sistema Nervoso Central/tratamento farmacológico
Citocinas/farmacologia
Inibidores Enzimáticos/farmacologia
Proteínas Tirosina Fosfatases Classe 5 Semelhantes a Receptores/antagonistas & inibidores
[Mh] Termos MeSH secundário: Animais
Anti-Inflamatórios não Esteroides/síntese química
Anti-Inflamatórios não Esteroides/química
Barreira Hematoencefálica/efeitos dos fármacos
Barreira Hematoencefálica/metabolismo
Proteínas de Transporte/síntese química
Proteínas de Transporte/química
Linhagem Celular
Sobrevivência Celular/efeitos dos fármacos
Doenças do Sistema Nervoso Central/metabolismo
Citocinas/síntese química
Citocinas/química
Relação Dose-Resposta a Droga
Inibidores Enzimáticos/síntese química
Inibidores Enzimáticos/química
Seres Humanos
Camundongos
Modelos Moleculares
Estrutura Molecular
Ratos
Proteínas Tirosina Fosfatases Classe 5 Semelhantes a Receptores/metabolismo
Relação Estrutura-Atividade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Carrier Proteins); 0 (Cytokines); 0 (Enzyme Inhibitors); 134034-50-7 (pleiotrophin); EC 3.1.3.48 (PTPRZ1 protein, human); EC 3.1.3.48 (Receptor-Like Protein Tyrosine Phosphatases, Class 5)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171225
[St] Status:MEDLINE


  3 / 15203 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29223589
[Au] Autor:Blanco MJ; La D; Coughlin Q; Newman CA; Griffin AM; Harrison BL; Salituro FG
[Ad] Endereço:Sage Therapeutics, Inc., 215 First Street, Cambridge, MA 02142, USA. Electronic address: Maria-Jesus.Blanco@sagerx.com.
[Ti] Título:Breakthroughs in neuroactive steroid drug discovery.
[So] Source:Bioorg Med Chem Lett;28(2):61-70, 2018 01 15.
[Is] ISSN:1464-3405
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Endogenous and synthetic neuroactive steroids (NASs) or neurosteroids are effective modulators of multiple signaling pathways including receptors for the γ-aminobutyric acid A (GABA ) and glutamate, in particular N-methyl-d-aspartate (NMDA). These receptors are the major inhibitory and excitatory neurotransmitters in the central nervous system (CNS), and there is growing evidence suggesting that dysregulation of neurosteroid production plays a role in numerous neurological disorders. The significant unmet medical need for treatment of CNS disorders has increased the interest for these types of compounds. In this review, we highlight recent progress in the clinical development of NAS drug candidates, in addition to preclinical breakthroughs in the identification of novel NASs, mainly for GABA and NMDA receptor modulation.
[Mh] Termos MeSH primário: Doenças do Sistema Nervoso Central/tratamento farmacológico
Descoberta de Drogas
Neurotransmissores/farmacologia
Receptores de GABA-A/metabolismo
Receptores de N-Metil-D-Aspartato/metabolismo
[Mh] Termos MeSH secundário: Animais
Doenças do Sistema Nervoso Central/metabolismo
Relação Dose-Resposta a Droga
Seres Humanos
Conformação Molecular
Neurotransmissores/química
Relação Estrutura-Atividade
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Neurotransmitter Agents); 0 (Receptors, GABA-A); 0 (Receptors, N-Methyl-D-Aspartate)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180216
[Lr] Data última revisão:
180216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171211
[St] Status:MEDLINE


  4 / 15203 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29334795
[Au] Autor:Lazewska D; Kiec-Kononowicz K
[Ad] Endereço:a Department of Technology and Biotechnology of Drugs , Jagiellonian University Medical College , Kraków , Poland.
[Ti] Título:Progress in the development of histamine H receptor antagonists/inverse agonists: a patent review (2013-2017).
[So] Source:Expert Opin Ther Pat;28(3):175-196, 2018 Mar.
[Is] ISSN:1744-7674
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Since years, ligands blocking histamine H receptor (H R) activity (antagonists/inverse agonists) are interesting targets in the search for new cures for CNS disorders. Intensive works done by academic and pharmaceutical company researchers have led to many potent and selective H R antagonists/inverse agonists. Some of them have reached to clinical trials. Areas covered: Patent applications from January 2013 to September 2017 and the most important topics connected with H R field are analysed. Espacenet, Patentscope, Pubmed, GoogleScholar or Cochrane Library online databases were principially used to collect all the materials. Expert opinion: The research interest in histamine H R field is still high although the number of patent applications has decreased during the past 4 years (around 20 publications). Complexity of histamine H R biology e.g. many isoforms, constitutive activity, heteromerization with other receptors (dopamine D , D , adenosine A ) and pharmacology make not easy realization and evaluation of therapeutic potential of anti-H R ligands. First results from clinical trials have verified potential utility of histamine H R antagonist/inverse agonists in some diseases. However, more studies are necessary for better understanding of an involvement of the histaminergic system in CNS-related disorders and helping more ligands approach to clinical trials and the market. Lists of abbreviations: hAChEI - human acetylcholinesterase inhibitor; hBuChEI - human butyrylcholinesterase inhibitor; hMAO - human monoamine oxidase; MAO - monoamine oxidase.
[Mh] Termos MeSH primário: Desenho de Drogas
Agonismo Inverso de Drogas
Antagonistas dos Receptores Histamínicos H3/farmacologia
[Mh] Termos MeSH secundário: Animais
Doenças do Sistema Nervoso Central/tratamento farmacológico
Doenças do Sistema Nervoso Central/fisiopatologia
Seres Humanos
Ligantes
Patentes como Assunto
Receptores Histamínicos H3/efeitos dos fármacos
Receptores Histamínicos H3/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Histamine H3 Antagonists); 0 (Ligands); 0 (Receptors, Histamine H3)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180117
[St] Status:MEDLINE
[do] DOI:10.1080/13543776.2018.1424135


  5 / 15203 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29311510
[Au] Autor:Takai K; Enomoto T
[Ad] Endereço:Drug Research Division, Sumitomo Dainippon Pharma Co., Ltd.
[Ti] Título:Discovery and Development of Muscarinic Acetylcholine M Activators as Promising Therapeutic Agents for CNS Diseases.
[So] Source:Chem Pharm Bull (Tokyo);66(1):37-44, 2018.
[Is] ISSN:1347-5223
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:Among the muscarinic acetylcholine receptor (mAChR) subtypes, the M receptor has been investigated as a promising drug target for the treatment of schizophrenia. These investigations have been based on findings from M -deficient mice studies as well as on the results of a clinical trial that used xanomeline, an M /M mAChRs-preferring agonist. Both orthosteric agonists and positive allosteric modulators of M mAChR have been reported as promising ligands that not only have antipsychotic effects, but can also improve cognitive impairment and motor dysfunction. However, challenges remain due to the high homology of the orthosteric binding site among all muscarinic receptors. In this review, we summarize our approach to the identification of M mAChR activators, orthosteric agonists, and positive allosteric modulators based on M mAChR structural information and structure-activity relationship studies. These findings indicate that selective M mAChR activators are promising potential therapeutic agents for several central nervous system conditions.
[Mh] Termos MeSH primário: Doenças do Sistema Nervoso Central/tratamento farmacológico
Descoberta de Drogas
Piridinas/farmacologia
Receptor Muscarínico M4/agonistas
Tiadiazóis/farmacologia
[Mh] Termos MeSH secundário: Animais
Doenças do Sistema Nervoso Central/metabolismo
Seres Humanos
Estrutura Molecular
Piridinas/química
Receptor Muscarínico M4/deficiência
Receptor Muscarínico M4/metabolismo
Relação Estrutura-Atividade
Tiadiazóis/química
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Pyridines); 0 (Receptor, Muscarinic M4); 0 (Thiadiazoles); 9ORI6L73CJ (xanomeline)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180110
[St] Status:MEDLINE
[do] DOI:10.1248/cpb.c17-00413


  6 / 15203 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29187683
[Au] Autor:Hoshino M; Suzuki Y; Akiyama H; Yamada K; Shima S; Mutoh T; Hasegawa Y
[Ad] Endereço:Department of Internal Medicine, Division of Neurology, St Marianna University School of Medicine.
[Ti] Título:[Efficacy of high-dose steroid pulse therapy for anti-galactocerebroside antibody-positive combined central and peripheral demyelination].
[So] Source:Rinsho Shinkeigaku;57(12):747-752, 2017 Dec 27.
[Is] ISSN:1882-0654
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:A 59-year-old man had been admitted to another hospital because of diplopia and thirst at the beginning of March and was diagnosed with diabetic ketoacidosis. He was referred to our hospital because he had limb weakness, dysarthria, and bilateral sensory impairment of the upper limbs, which worsened rapidly from the middle of March, although plasma glucose had been well controlled after the initiation of insulin therapy in the previous hospital. Contrast spinal MRI in our hospital revealed hyperintense lesions at the level of C4 to C5 and T10. The level of myelin basic protein was high (1,260 pg/ml) in the cerebrospinal fluid and serum anti-neurofascin antibody was negative. Nerve conduction study showed typical findings of demyelination at least 2 regions. Although anti-neurofascin antibody was negative, he was diagnosed with combined central and peripheral demyelination (CCPD) based on these clinical findings. After the repeated methylprednisolone pulse therapy for five times, the hyperintense lesions of the spinal cord disappeared gradually. He was bedridden at the beginning of his hospitalization but could ambulate with a cane on discharge 2 months after the admission. Then we received the result of anti-galactocerebroside antibody test as positive. This case suggested that high-dose steroid pulse therapy is safe and may be effective for anti-galactocerebroside antibody-positive CCPD.
[Mh] Termos MeSH primário: Autoanticorpos/sangue
Doenças do Sistema Nervoso Central/diagnóstico
Doenças Desmielinizantes/diagnóstico
Galactosilceramidas/imunologia
Imunoglobulina G/sangue
Metilprednisolona/administração & dosagem
Doenças do Sistema Nervoso Periférico/diagnóstico por imagem
[Mh] Termos MeSH secundário: Biomarcadores/sangue
Moléculas de Adesão Celular/imunologia
Seres Humanos
Imagem por Ressonância Magnética
Masculino
Meia-Idade
Proteína Básica da Mielina/sangue
Fatores de Crescimento Neural/imunologia
Pulsoterapia
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Autoantibodies); 0 (Biomarkers); 0 (Cell Adhesion Molecules); 0 (Galactosylceramides); 0 (Immunoglobulin G); 0 (Myelin Basic Protein); 0 (NFASC protein, human); 0 (Nerve Growth Factors); X4W7ZR7023 (Methylprednisolone)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180112
[Lr] Data última revisão:
180112
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171201
[St] Status:MEDLINE
[do] DOI:10.5692/clinicalneurol.cn-000977


  7 / 15203 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28988704
[Au] Autor:Bentley RT; Taylor AR; Thomovsky SA
[Ad] Endereço:Neurology and Neurosurgery, Department of Veterinary Clinical Sciences, Purdue University College of Veterinary Medicine, Purdue University, Lynn Hall, 625 Harrison Street, West Lafayette, IN 47907, USA. Electronic address: rbentley@purdue.edu.
[Ti] Título:Fungal Infections of the Central Nervous System in Small Animals: Clinical Features, Diagnosis, and Management.
[So] Source:Vet Clin North Am Small Anim Pract;48(1):63-83, 2018 Jan.
[Is] ISSN:1878-1306
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Small animal mycoses vary geographically. Different clinical presentations are seen in animals with infection of the central nervous system (CNS), including multifocal meningoencephalomyelitis, intracranial lesions that accompany sinonasal lesions, rapidly progressive ventriculitis, or solitary granuloma of the brain or spinal cord. Systemic, nasal, or extraneural clinical signs are common but, especially in granuloma cases, do not always occur. Surgery may have a diagnostic and therapeutic role in CNS granuloma. There have been recent advancements in serology. Fluconazole, voriconazole, and posaconazole cross the blood-brain barrier, but voriconazole is neurotoxic to cats. Liposomal and lipid-encapsulated formulations of amphotericin B are preferred.
[Mh] Termos MeSH primário: Doenças do Gato/microbiologia
Doenças do Sistema Nervoso Central/veterinária
Doenças do Cão/microbiologia
Micoses/veterinária
[Mh] Termos MeSH secundário: Animais
Antifúngicos/uso terapêutico
Doenças do Gato/diagnóstico
Doenças do Gato/tratamento farmacológico
Doenças do Gato/fisiopatologia
Gatos
Sistema Nervoso Central/microbiologia
Doenças do Sistema Nervoso Central/diagnóstico
Doenças do Sistema Nervoso Central/microbiologia
Doenças do Sistema Nervoso Central/fisiopatologia
Doenças do Cão/diagnóstico
Doenças do Cão/tratamento farmacológico
Doenças do Cão/fisiopatologia
Cães
Micoses/diagnóstico
Micoses/tratamento farmacológico
Micoses/fisiopatologia
Prognóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antifungal Agents)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171222
[Lr] Data última revisão:
171222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171010
[St] Status:MEDLINE


  8 / 15203 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28747403
[Au] Autor:Laube G; Bernstein HG
[Ad] Endereço:Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Integrative Neuroanatomy, Berlin, Germany gregor.laube@charite.de.
[Ti] Título:Agmatine: multifunctional arginine metabolite and magic bullet in clinical neuroscience?
[So] Source:Biochem J;474(15):2619-2640, 2017 07 26.
[Is] ISSN:1470-8728
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Agmatine, the decarboxylation product of arginine, was largely neglected as an important player in mammalian metabolism until the mid-1990s, when it was re-discovered as an endogenous ligand of imidazoline and α -adrenergic receptors. Since then, a wide variety of agmatine-mediated effects have been observed, and consequently agmatine has moved from a wallflower existence into the limelight of clinical neuroscience research. Despite this quantum jump in scientific interest, the understanding of the anabolism and catabolism of this amine is still vague. The purification and biochemical characterization of natural mammalian arginine decarboxylase and agmatinase still are open issues. Nevertheless, the agmatinergic system is currently one of the most promising candidates in order to pharmacologically interfere with some major diseases of the central nervous system, which are summarized in the present review. Particularly with respect to major depression, agmatine, its derivatives, and metabolizing enzymes show great promise for the development of an improved treatment of this common disease.
[Mh] Termos MeSH primário: Agmatina/metabolismo
Arginina/metabolismo
[Mh] Termos MeSH secundário: Envelhecimento/metabolismo
Animais
Doenças do Sistema Nervoso Central/metabolismo
Seres Humanos
Transtornos Mentais/metabolismo
Redes e Vias Metabólicas
Neuralgia/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
70J407ZL5Q (Agmatine); 94ZLA3W45F (Arginine)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:171217
[Lr] Data última revisão:
171217
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170728
[St] Status:MEDLINE
[do] DOI:10.1042/BCJ20170007


  9 / 15203 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28453910
[Au] Autor:Johnston DL; Alonzo TA; Gerbing RB; Aplenc R; Woods WG; Meshinchi S; Gamis AS
[Ad] Endereço:Division of Hematology/Oncology, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada.
[Ti] Título:Central nervous system disease in pediatric acute myeloid leukemia: A report from the Children's Oncology Group.
[So] Source:Pediatr Blood Cancer;64(12), 2017 Dec.
[Is] ISSN:1545-5017
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The prognostic impact of central nervous system (CNS) involvement in children with acute myeloid leukemia (AML) has varied in past trials, and controversy exists over the degree of involvement requiring intensified CNS therapy. Two recent Children's Oncology Group protocols, AAML03P1 and AAML0531, directed additional intrathecal (IT) therapy to patients with CNS2 (≤5 white blood cell [WBC] with blasts) or CNS3 (>5 WBC with blasts or CNS symptoms) disease at diagnosis. METHODS: We examined disease characteristics and outcomes of the 1,344 patients on these protocols, 949 with CNS1 (no blasts), 217 with CNS2, and 178 with CNS3, with the latter two receiving additional IT therapy. RESULTS: Young age (P = 0.003), hyperleukocytosis (P < 0.001), and the presence of inversion 16 (P < 0.001) were the only factors more prevalent in patients with CNS2 or CNS3 disease. Complete remission at the end of induction (EOI) 2 was achieved less often in patients with CNS involvement (P < 0.001). From diagnosis, event-free survival (EFS) for patients with CNS involvement was significantly worse (P < 0.001), whereas overall survival (OS) was not (P = 0.16). From the EOI1, there was a higher relapse rate (RR) and worse disease-free survival (DFS), but less impact on OS (CNS1:DFS 58.9%, RR 34.1%, OS 69.3%; CNS2:DFS 53.2%, RR 40.9%, OS 74.7%; CNS3:DFS 45.2%, RR 48.8%, OS 60.8%; P = 0.006, P < 0.001, P = 0.045, respectively). Multivariable analysis showed that independently CNS2 and CNS3 status adversely affected RR and DFS. Traumatic diagnostic lumbar puncture was not associated with worse outcome. CONCLUSIONS: CNS leukemia confers greater relapse risk despite more aggressive locally directed therapy. Novel approaches need to be investigated in this group of patients.
[Mh] Termos MeSH primário: Doenças do Sistema Nervoso Central/etiologia
Leucemia Mieloide Aguda/complicações
[Mh] Termos MeSH secundário: Seres Humanos
Lactente
Prognóstico
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171201
[Lr] Data última revisão:
171201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1002/pbc.26612


  10 / 15203 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28745675
[Au] Autor:Yakovlev AA; Yakovlev SA; Smochilin AG; Yakovleva MV
[Ad] Endereço:Federal State Budgetary Educational Institution of Higher Education 'Academician I.P. Pavlov First St. Petersburg State Medical University' of the Ministry of Healthcare of the Russian Federation, St. Petersburg, Russia; Federal State Budgetary Educational Institution of Higher Education 'St. Peters
[Ti] Título:[A rare case of rapidly progressing primary diffuse meningeal sarcomatosis of the brain and spinal cord].
[Ti] Título:Redkii sluchai bystroprogressiruiushchego pervichnogo diffuznogo meningeal'nogo sarkomatoza golovnogo i spinnogo mozga..
[So] Source:Zh Nevrol Psikhiatr Im S S Korsakova;117(6):73-78, 2017.
[Is] ISSN:1997-7298
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:Currently the differential diagnosis of anaplastic meningiomas often is quite complex. An interpretation of the data of radiological studies does not allow the exclusion of diseases with similar clinical course and character of a lesion, such as primary lymphoma and tuberculosis of the central nervous system, neurosarcoidosis and others. The article presents a clinical case, representing a rare and difficult to diagnose variant of anaplastic meningioma with extremely aggressive nature of the current and widespread involvement of the brain and spinal cord.
[Mh] Termos MeSH primário: Doenças do Sistema Nervoso Central/diagnóstico
Neoplasias Meníngeas/diagnóstico
Meningioma/diagnóstico
Sarcoidose/diagnóstico
[Mh] Termos MeSH secundário: Adulto
Doenças do Sistema Nervoso Central/diagnóstico por imagem
Diagnóstico Diferencial
Seres Humanos
Imagem por Ressonância Magnética
Masculino
Neoplasias Meníngeas/diagnóstico por imagem
Meningioma/diagnóstico por imagem
Sarcoidose/diagnóstico por imagem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171128
[Lr] Data última revisão:
171128
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170727
[St] Status:MEDLINE
[do] DOI:10.17116/jnevro20171176173-78



página 1 de 1521 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde